Your current location is:Fxscam News > Exchange Dealers
Tesla's free cash flow may turn negative, Wells Fargo maintains "sell" rating.
Fxscam News2025-07-25 20:49:33【Exchange Dealers】0People have watched
IntroductionInstitutions with foreign exchange licenses in China,Foreign Exchange Trading Platform App Download,On Tuesday, Wells Fargo, an American investment bank, released its latest research report warning th
On Tuesday,sellInstitutions with foreign exchange licenses in China Wells Fargo, an American investment bank, released its latest research report warning that the fundamentals of electric vehicle giant Tesla are continuously deteriorating. It predicts that Tesla's free cash flow (FCF) will turn negative in 2025 for the first time since 2018, reiterating its "sell" rating with a price target of $120.
Wells Fargo's chief analyst Colin Langan pointed out that Tesla faces multiple pressures, including sales, margins, working capital, and capital expenditures, which collectively cast a troubling outlook on its overall financial performance.
Difficulties in Meeting Q2 Delivery Expectations
Wells Fargo predicts that Tesla's vehicle deliveries in the second quarter of 2024 will fall significantly short of expectations. Analysis shows that to meet the market consensus estimate of 411,000 units, Tesla would need to achieve a month-on-month increase of over 50% in June, which is almost impossible given the current market and operational context.
Wells Fargo has lowered its estimate for second-quarter deliveries to 343,000 units, about 17% less than the Wall Street consensus. This implies that Tesla would experience delivery growth stagnation for two consecutive quarters.
From an annual perspective, Wells Fargo expects Tesla's total deliveries in 2024 to decline by 21% year-on-year, marking the first drastic contraction in recent years.
Pressure on Both Margins and Cash Flow
While sales are weak, margins are also taking a hit. Langan noted that revenue from Zero Emission Vehicle (ZEV) credits is decreasing, further weakening profitability. Worse still, Tesla faces over $11 billion in capital expenditure demands, coupled with potential tightness in working capital, all of which are eroding its free cash flow.
Wells Fargo believes that under these circumstances, Tesla's free cash flow in 2025 will shift from positive to negative, marking the first instance since 2018.
Lackluster Strategic Development Undermines Market Confidence
In terms of products and strategy, Wells Fargo expresses concerns about Tesla's future growth prospects. The bank points out that the market-anticipated "affordable" electric vehicle still lacks a clear timeline, putting Tesla at a disadvantage in the highly competitive mid- to low-end market.
Meanwhile, Tesla's actively promoted "fully automated driving taxi" project has yet to reassure investors. According to Wells Fargo research, the pilot program in Austin is progressing slowly, with limited scope and strict regulation. Any technical mishap could trigger comprehensive regulatory tightening, severely impacting business development.
Langan bluntly stated: "This project has yet to demonstrate its capability as a short-term profit growth engine and could potentially be a source of risk."
Wells Fargo Maintains "Sell" Rating and $120 Target Price
In conclusion, Wells Fargo has decided to maintain its "sell" rating on Tesla, with a target price of $120. This target is significantly discounted compared to the current stock price of approximately $316, indicating Wells Fargo's extremely cautious attitude towards Tesla's future performance.
Although Tesla's stock price has recently rebounded in the market, the potential deterioration of its fundamentals and financial condition could continue to exert pressure over the coming quarters.
Market Impact Observations
Wells Fargo's negative rating has caused a certain resonance in the market. By the market close on Tuesday, Tesla's stock price fell by 3.88%, closing at $316.35, indicating that investor anxiety about its financial prospects is partially reflected in trading.
In the future, whether Tesla can simultaneously focus on product innovation and cost control will be crucial to reversing its downturn. Wells Fargo's warning also reminds the market that tech giants under the halo of high valuations could face the harsh reality of cash flow challenges.
Risk Warning and DisclaimerThe market carries risks, and investment should be cautious. This article does not constitute personal investment advice and has not taken into account individual users' specific investment goals, financial situations, or needs. Users should consider whether any opinions, viewpoints, or conclusions in this article are suitable for their particular circumstances. Investing based on this is at one's own responsibility.
Very good!(31)
Related articles
- Is Ridder Trader Group legal? What legal responsibilities do Light Business Academy members bear?
- April 18, 2024, Daily Morning Market Update
- US rate hike expectations rise, dollar strengthens, oil prices fall.
- The situation in the Black Sea pushes up wheat futures prices.
- Financial guru Mark Bouris criticizes Australia's real estate policies
- Oil prices rebounded, but the outlook is bearish. Watch OPEC+ and geopolitics
- CME and Nasdaq will launch new Bitcoin derivatives, likely affecting the crypto market.
- The Trump family is involved in the rapidly growing cryptocurrency sector.
- Market Insights: Jan 15, 2024
- Boeing workers are authorized to strike, posing challenges for leadership.
Popular Articles
Webmaster recommended
Market Insights: Nov 30th, 2023
Asian LNG's price premium over U.S. levels is at its 2024 peak.
Global grain market turmoil: Will a bumper soybean harvest impact prices?
Why haven't logistics issues weakened corn basis resilience amid global trade shifts?
9.7 Industry News: Australia's ASIC tightens distribution of high
Australia Star Group announces new CEO and General Manager, previously worked at Blackstone.
Australia Star Group announces new CEO and General Manager, previously worked at Blackstone.
Novo Nordisk's weight loss drug Wegovy approved in China, sales time and price not announced